ARCHIVES

Gilotrif Increases PFS Compared to Erlotinib In LUX-Lung 8 Phase III Head-to-Head Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

Senate Committee Ok’s $1.9 Billion Budget For NCI, Same As House Appropriation

July 29, 1994

Managed Care Limits Access To Trials, Cancer Panel Says

August 11, 1995

ACS Asks Congress For $1.32 Billion NCI ’87 Budget

April 4, 1986

Micafungin Bests Fluconazole In Phase III Antifungal Trial

November 29, 2002

PhRMA’s New Ethics Code Prohibits Trinkets, Dinners; Speaking Fees Still OK.

July 11, 2008

Funding Opportunities: NCI Offers Grant Supplements

March 5, 1999